Termination Agreement for Target Collaboration Deed between Immunocore Limited and Adaptimmune Limited
Immunocore Limited and Adaptimmune Limited have agreed to terminate their Target Collaboration Deed, originally dated January 28, 2015. The termination will take effect on March 1, 2017, with the original agreement remaining in force until that date. Certain clauses from the original deed will continue to apply after termination. Other agreements between the two companies are not affected by this termination. The agreement becomes effective upon signature by Adaptimmune Limited.
Exhibit 10.14
To: CEO and CBO
Adaptimmune Limited
91 Milton Park
Abingdon
Oxfordshire
OX14 4RY
Date: 12th September 2016
Dear Sirs
Re: Agreement to terminated the Target Collaboration Deed dated 28 January 2015
This letter confirms the agreement of both Immunocore Limited and Adaptimmune Limited to terminate the Target Collaboration Deed entered into between them and dated 28 January 2015. Such mutually agreed termination shall become effective as of 1 March 2017 and up until such date, the terms of the Target Collaboration Deed shall continue in full force and effect.
The Parties also agree and confirm that the following clauses shall continue in full force and effect following termination of the Deed: 1(to the extent necessary for interpretation of surviving provisions), 2, 3.1, 3.3, 3.4, 3.5, 4.8, 4.9, 4.10, 5.1, 5.4.4, 6 (including the licences granted in clause 6.4A), 7 (to the extent any payment obligation remains outstanding), 9, 11.6, 13, 14, 21 (to the extent necessary for interpretation and enforcement or surviving terms).
Other agreements between Immunocore Limited and Adaptimmune Limited shall remain unaffected by the termination of the Target Collaboration Deed. This letter shall become effective on the date of signature by and on behalf of Adaptimmune Limited below.
| Yours faithfully |
|
|
|
|
| /s/ Eliot Forster |
|
On behalf of Immunocore Limited
Confirmed and agreed by Adaptimmune Limited
| Signed by: | /s/ James Noble |
|
|
| James Noble, CEO |
|
| Date: 8 November 2016 |
| |
| On behalf of Adaptimmune Limited |
| |
